Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Willing and able to provide written informed consent
HCV RNA ≥ 10\^4 IU/mL at screening
Chronic HCV infection (≥ 6 months)
HCV treatment naive or treatment experienced with an interferon (IFN)-based regimen
Use of protocol specified methods of contraception
You may not be if
Current or prior history of clinically significant illness that may interfere with participation in the study
Screening ECG with clinically significant abnormalities
Laboratory parameters outside the acceptable range at screening
Pregnant or nursing female
Chronic liver disease not caused by HCV
Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
Clareo Health | Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy
